Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Simponi (golimumab by Year
Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%) (%)
Merck Simponi (golimumab: -23.0% in FY2024, down 24.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| Simponi | 184 | 172 | 189 | 543 | 180 | 180 | 179 | 171 | 710 | N/M | N/M | -24 | -23”
Source: Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Reported in Form 8-K Table 3 / 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Simponi (golimumab — immunology, legacy ex-U.S. marketing rights) — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | -23.0% | -24.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 1.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | -2.0% | -3.0 pts | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2020 | Dec 31, 2020 | 1.0% | +8.0 pts | Form 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗ |
| FY2019 | Dec 31, 2019 | -7.0% | -16.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 9.0% | +2.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 7.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Simponi (golimumab (%), annual FY2017–FY2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-simponi-ww-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.